Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GNRHR | P30968 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PPM1B | O75688 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5790866 | 0.85 | KMT2A (0.56) | MEN1KMT2AMAPTGNRHRALDH1A1 | |
| SCHEMBL1724543 | 0.84 | TDP1 (0.44) | MEN1KMT2AGNRHRALDH1A1TSHR | |
| SCHEMBL1724542 | 0.84 | TDP1 (0.44) | MEN1KMT2AGNRHRALDH1A1TSHR | |
| SCHEMBL15158080 | 0.84 | MEN1 (0.51) | MEN1KMT2AMAPTGNRHRALDH1A1 | |
| SCHEMBL3574409 | 0.83 | MEN1 (0.59) | MEN1KMT2AMAPTALDH1A1TSHR | |
| SCHEMBL3574412 | 0.83 | MEN1 (0.59) | MEN1KMT2AMAPTALDH1A1TSHR | |
| SCHEMBL8597654 | 0.83 | MEN1 (0.50) | MEN1KMT2AMAPTGNRHRALDH1A1 | |
| SCHEMBL8597658 | 0.83 | MEN1 (0.50) | MEN1KMT2AMAPTGNRHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL8597897 | 0.81 | MEN1 (0.49) | MEN1KMT2AMAPTGNRHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL8596879 | 0.81 | MEN1 (0.49) | MEN1KMT2AMAPTGNRHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1357908-A4 | ACYL SULFAMIDES FOR TREATMENT OF OBESITY, DIABETES AND LIPID DISORDERS | MERCK & CO INC (US) | 2009-07-15 | — | — | EP | disclosed |
| US-6852738-B2 | Potent ligands for PPAR gamma and generally have antagonist or partial agonist activity. The compoundsare for treatment, control or prevention of obesity, non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, | MERCK & CO., INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040073037-A1 | Anticholesterol agents; cardiovascular disorders; antiinflammatory agents; peroxisome proliferator activator receptor antagonist | MERCK SHARP & DOHME CORP. | 2004-04-15 | — | — | US | disclosed |
| EP-1357908-A2 | ACYL SULFAMIDES FOR TREATMENT OF OBESITY, DIABETES AND LIPID DISORDERS | Merck & Co., Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002060388-A2 | ACYL SULFAMIDES FOR TREATMENT OF OBESITY, DIABETES AND LIPID DISORDERS | MERCK & CO., INC. (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040073037-A1 | Anticholesterol agents; cardiovascular disorders; antiinflammatory agents; peroxisome proliferator activator receptor antagonist | PPARA, PPARD, PPARG | MEN1 4883/4885KMT2A 2530/4885MAPT 4762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.